Masanori Isobe

Masanori Isobe

Auto-generated profile, based on publicly available information

Masanori Isobe

Department of Obstetrics and Gynecology, Gifu University Graduate School of Medicine, Gifu, Japan

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
MOMika Okazawa-Sakai
Mika Okazawa-Sakai
SSShunsuke A. Sakai
Shunsuke A. Sakai
IHIchinosuke Hyodo
Ichinosuke Hyodo
SHSatoshi Horasawa
Satoshi Horasawa
KSKentaro Sawada
Kentaro Sawada
DADaisuke Aoki
Daisuke Aoki
Okazawa-Sakai M, et al. J Gynecol Oncol. 2024 Oct;36:e38. https://doi.org/10.3802/jgo.2025.36.e38

1 October 2009 in Gynecologic Oncology
Verified
Journal Article
Closed access
EKEiji Kobayashi
Eiji Kobayashi
TITadashi Iwamiya
Tadashi Iwamiya
MIMasanori Isobe
Masanori Isobe
TMTakahito Miyake
Takahito Miyake
YSYasuhiko Shiki
Yasuhiko Shiki
MYMasato Yamasaki
Masato Yamasaki

13 May 2025 in JMIR Research Protocols
Verified
Journal Article
Open access
KKKyoko Kikuno
Kyoko Kikuno
RARyuta Asada
Ryuta Asada
TITakuma Ishihara
Takuma Ishihara
YBYoshimasa Bomoto
Yoshimasa Bomoto
SMSaki Murase
Saki Murase
KMKen-Ichirou Morishige
Ken-Ichirou Morishige
Background: The treatment of endometriosis includes analgesics, hormone therapy, and surgery. Even after surgical removal of endometriotic lesions, the risk of recurrence remains high once the normal menstrual cycle resumes. Therefore, long-term hormone therapy is essential to prevent recurrence. Among hormonal treatments, low-dose estrogen progestin preparations are not recommended for patients older than 40 years due to the increased risk of thrombotic side effects. In contrast, dienogest does not carry a thrombotic risk, making it a suitable option for older patients. Although dienogest requires long-term administration until menopause in patients with endometriosis, data on its long-term efficacy and potential adverse effects remain limited. In particular, comparative studies assessing the safety and effectiveness of long-term use of dienogest at different doses (1 mg/day vs 2 mg/day) have not been conducted, highlighting the need for further investigation. Objective: The purpose of this study is to investigate the efficacy and the incidence of adverse events of dienogest 1 mg/day after 48 weeks in patients with dysmenorrhea due to endometriosis, compared with dienogest 2 mg/day. Methods: This randomized, open-label, parallel-group, dose-comparison, multicenter trial follows the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) 2013 guidelines and is conducted at 6 centers in Japan. Participants are randomly assigned in a 1:1 ratio to receive either dienogest 1 mg/day or 2 mg/day. The drug is administered for 48 weeks, and its therapeutic effects and side effects are evaluated. Hospital visits include the use of questionnaires, vital sign measurements, imaging studies (magnetic resonance imaging and ultrasound), blood tests, and bone density assessments. The primary endpoint is the change in the pain visual analog scale (VAS) score from baseline to 48 weeks. The VAS is a 10 cm horizontal scale where 0 cm represents no pain and 10 cm represents the maximum imaginable pain; participants indicate their pain level on the scale, and the change is analyzed over time. The target sample size is 88, determined with a noninferiority margin based on existing literature. The protocol was approved by the Nagoya City University Hospital Clinical Research Review Board. Findings will be presented at academic conferences and published in peer-reviewed journals. Results: Currently, data collection is ongoing. The first participant was enrolled in August 2021. As of March 22, 2025, a total of 88 participants had been enrolled in this clinical trial. Conclusions: This is the first trial to compare efficacy and safety between 1 mg/day and 2 mg/day of long-term dienogest use in patients with dysmenorrhea caused by endometriosis. Combining diagnostic imaging with patient questionnaires and blood tests allows the determination of efficacy against endometriosis itself. Trial Registration: Japan Registry of Clinical Trials jRCTs041210016; https://jrct.mhlw.go.jp/en-latest-detail/jRCTs041210016 International Registered Report Identifier (IRRID): DERR1-10.2196/66246

24 January 2013 in Asian Journal of Endoscopic Surgery
Verified
Journal Article
Closed access
PDF file
YTYusuke Tanaka
Yusuke Tanaka
SKShinsuke Koyama
Shinsuke Koyama
MKMasaki Kobayashi
Masaki Kobayashi
SKSatoshi Kubota
Satoshi Kubota
RNRyo Nakamura
Ryo Nakamura
YSYasuhiko Shiki
Yasuhiko Shiki

24 October 2025 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
KKKyoko Kikuno
Kyoko Kikuno
RARyuta Asada
Ryuta Asada
TITakuma Ishihara
Takuma Ishihara
KMKen-Ichirou Morishige
Ken-Ichirou Morishige
KCKenro Chikazawa
Kenro Chikazawa
MIMasanori Isobe
Masanori Isobe
Introduction Dienogest (DNG) is widely used to manage endometriosis-associated pain; however, long-term data comparing low and standard doses are limited. Therefore, this study aimed to evaluate the efficacy and safety of 48-week DNG treatment (1 mg/day vs. 2 mg/day) in patients with endometriosis-related dysmenorrhea (composite score). Methods In this randomized, open-label, parallel-group, trial, 88 patients with endometriosis were enrolled, all of whom had at least one ovarian endometriotic cyst confirmed by imaging. Other phenotypes of endometriosis, such as deep infiltrating or peritoneal lesions, were not systematically assessed and may have been present. Patients were randomized to receive either 1-mg/day or 2-mg/day DNG. The primary endpoint was the change in menstrual pain measured using a visual analog scale (VAS). Secondary endpoints included changes in the dysmenorrhea score, ovarian endometrioma volume, serum estradiol levels, bone mineral density (BMD), and menopausal symptoms. Results Both groups demonstrated a significant reduction in menstrual pain (VAS). The mean VAS scores decreased by 44.63 and 54.19 mm in the 1-mg and 2-mg groups, respectively. However, the between-group difference (– 9.57 mm; 95% confidence interval: − 22.7 to 3.56) was not above the predefined non-inferiority margin of – 15 mm; thus, non-inferiority of the 1-mg dose could not be confirmed. Improvements in dysmenorrhea scores and endometrioma volume were also observed in both groups, although greater effects were noted in the 2-mg group than in the 1-mg group. Serum estradiol suppression was comparable between the groups, whereas BMD loss was less pronounced in the 1-mg group than in the 2-mg group. Conclusions This study did not demonstrate statistical non-inferiority of 1-mg/day DNG treatment over 2-mg/day DNG treatment for pain relief. These results suggest that the 2-mg/day dose may offer more robust analgesic effects, particularly during the early treatment phase. However, 1-mg/day DNG still showed meaningful symptom improvement with fewer adverse events than 2-mg/day DNG, supporting its potential use in selected patients requiring long-term therapy. Trial Registration Japan Registry of Clinical Trials, trial registration number: jRCTs041210016.

7 November 2026 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
MOMika Okazawa-Sakai
Mika Okazawa-Sakai
TFTakao Fujisawa
Takao Fujisawa
TCTatsuyuki Chiyoda
Tatsuyuki Chiyoda
HYHiroshi Yagi
Hiroshi Yagi
IHIchinosuke Hyodo
Ichinosuke Hyodo
DADaisuke Aoki
Daisuke Aoki
Okazawa-Sakai M, et al. J Gynecol Oncol. 2027 ;38:e11. https://doi.org/10.3802/jgo.2027.38.e11